{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:42:37Z","timestamp":1792629757023,"version":"4.5.0"},"reference-count":134,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,1,21]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>\n                    Chronic graft-\n                    <jats:italic>versus<\/jats:italic>\n                    -host disease (cGvHD) is a common complication after allogeneic haematopoietic stem cell transplantation, characterised by a broad disease spectrum that can affect virtually any organ. Although pulmonary cGvHD is a less common manifestation, it is of great concern due to its severity and poor prognosis. Optimal management of patients with pulmonary cGvHD is complicated and no standardised approach is available. The purpose of this joint European Respiratory Society (ERS) and European Society for Blood and Marrow Transplantation task force was to develop evidence-based recommendations regarding the treatment of pulmonary cGvHD phenotype bronchiolitis obliterans syndrome in adults. A multidisciplinary group representing specialists in haematology, respiratory medicine and methodology, as well as patient advocates, formulated eight PICO (patient, intervention, comparison, outcome) and two narrative questions. Following the ERS standardised methodology, we conducted systematic reviews to address these questions and used the Grading of Recommendations Assessment, Development and Evaluation approach to develop recommendations. The resulting guideline addresses common therapeutic options (inhalation therapy, fluticasone-azithromycin-montelukast, imatinib, ibrutinib, ruxolitinib, belumosudil, extracorporeal photopheresis and lung transplantation), as well as other aspects of general management, such as lung functional and radiological follow-up and pulmonary rehabilitation, for adults with pulmonary cGvHD phenotype bronchiolitis obliterans syndrome. These recommendations include important advancements that could be incorporated in the management of adults with pulmonary cGvHD, primarily aimed at improving and standardising treatment and improving outcomes.\n                  <\/jats:p>","DOI":"10.1183\/13993003.01727-2023","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T11:40:16Z","timestamp":1710416416000},"page":"2301727","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-\n                    <i>versus<\/i>\n                    -host disease in adults"],"prefix":"10.1183","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-5914","authenticated-orcid":false,"given":"Saskia","family":"Bos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Shing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Beestrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Linke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-1273","authenticated-orcid":false,"given":"Courtney","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-9251","authenticated-orcid":false,"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2026061109155413000_63.3.2301727.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"2026061109155413000_63.3.2301727.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.09.006"},{"key":"2026061109155413000_63.3.2301727.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02530.x"},{"key":"2026061109155413000_63.3.2301727.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2018"},{"key":"2026061109155413000_63.3.2301727.5","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","article-title":"History of hematopoietic cell transplantation: challenges and progress","volume":"105","author":"Granot","year":"2020","journal-title":"Haematologica"},{"key":"2026061109155413000_63.3.2301727.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703472"},{"key":"2026061109155413000_63.3.2301727.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02617-2017"},{"key":"2026061109155413000_63.3.2301727.8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccm.2017.07.003","article-title":"Bronchiolitis obliterans syndrome and other late pulmonary complications after allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Bergeron","year":"2017","journal-title":"Clin Chest Med"},{"key":"2026061109155413000_63.3.2301727.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.018"},{"key":"2026061109155413000_63.3.2301727.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.03.009"},{"key":"2026061109155413000_63.3.2301727.11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/17476348.2019.1557049","article-title":"Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Bondeelle","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"2026061109155413000_63.3.2301727.13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2213-2600(22)00001-7","article-title":"Pulmonary graft-versus-host disease and chronic lung allograft dysfunction: two sides of the same coin?","volume":"10","author":"Bos","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026061109155413000_63.3.2301727.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"2026061109155413000_63.3.2301727.15","unstructured":"Nagavci B , Tonia T , Bush A , et al. ERS Handbook for Clinical Practice Guidelines: Methodological Guidance for Developing ERS Clinical Practice Guidelines . Sheffield, European Respiratory Society, 2021."},{"key":"2026061109155413000_63.3.2301727.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2016"},{"key":"2026061109155413000_63.3.2301727.17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","article-title":"Budesonide\/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation","volume":"191","author":"Bergeron","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026061109155413000_63.3.2301727.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705637"},{"key":"2026061109155413000_63.3.2301727.19","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.21037\/jtd-19-3475","article-title":"Efficacy and safety of high-dose budesonide\/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant","volume":"12","author":"Kim","year":"2020","journal-title":"J Thorac Dis"},{"key":"2026061109155413000_63.3.2301727.20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705877"},{"key":"2026061109155413000_63.3.2301727.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2026061109155413000_63.3.2301727.22","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-71"},{"key":"2026061109155413000_63.3.2301727.23","first-page":"CD012620","article-title":"Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis","volume":"12","author":"Oba","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026061109155413000_63.3.2301727.24","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.311"},{"key":"2026061109155413000_63.3.2301727.25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00020804"},{"key":"2026061109155413000_63.3.2301727.27","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.1"},{"key":"2026061109155413000_63.3.2301727.28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jtct.2022.01.021","article-title":"Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplantation and investigation into bronchiolitis obliterans syndrome pathogenesis","volume":"28","author":"Williams","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbmt.2019.10.025","article-title":"Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation","volume":"26","author":"Cheng","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jama.2017.9938","article-title":"Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial","volume":"318","author":"Bergeron","year":"2017","journal-title":"JAMA"},{"key":"2026061109155413000_63.3.2301727.31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026061109155413000_63.3.2301727.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60953-2"},{"key":"2026061109155413000_63.3.2301727.33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/TP.0b013e31824db9da","article-title":"Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection","volume":"94","author":"Vos","year":"2012","journal-title":"Transplantation"},{"key":"2026061109155413000_63.3.2301727.34","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.2022016926","article-title":"Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation","volume":"140","author":"Vallet","year":"2022","journal-title":"Blood"},{"key":"2026061109155413000_63.3.2301727.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.06.009"},{"key":"2026061109155413000_63.3.2301727.36","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/bmt.2015.120","article-title":"Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation","volume":"50","author":"Watanabe","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231159"},{"key":"2026061109155413000_63.3.2301727.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204750"},{"key":"2026061109155413000_63.3.2301727.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-494278"},{"key":"2026061109155413000_63.3.2301727.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204156"},{"key":"2026061109155413000_63.3.2301727.41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3325\/cmj.2016.57.247","article-title":"Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease","volume":"57","author":"S\u00e1nchez-Ortega","year":"2016","journal-title":"Croat Med J"},{"key":"2026061109155413000_63.3.2301727.42","doi-asserted-by":"crossref","first-page":"e14255","DOI":"10.1111\/ctr.14255","article-title":"Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: real-life experience of the Spanish group of hematopoietic transplantation (GETH)","volume":"35","author":"Parra Salinas","year":"2021","journal-title":"Clin Transplant"},{"key":"2026061109155413000_63.3.2301727.43","doi-asserted-by":"crossref","first-page":"9636897221113789","DOI":"10.1177\/09636897221113789","article-title":"Results of multicenter phase II study with imatinib mesylate in allogeneic recipients with steroid-refractory chronic GVHD","volume":"31","author":"Baek","year":"2022","journal-title":"Cell Transplant"},{"key":"2026061109155413000_63.3.2301727.44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41409-022-01898-x","article-title":"Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and\/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"58","author":"Srour","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00509"},{"key":"2026061109155413000_63.3.2301727.46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtct.2021.05.019","article-title":"An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease","volume":"27","author":"Doki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.47","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41409-021-01318-6","article-title":"Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection","volume":"56","author":"Kaloyannidis","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793786"},{"key":"2026061109155413000_63.3.2301727.49","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.50","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41409-019-0662-6","article-title":"Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease","volume":"55","author":"Streiler","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.51","doi-asserted-by":"crossref","first-page":"668825","DOI":"10.3389\/fphar.2021.668825","article-title":"Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026061109155413000_63.3.2301727.52","doi-asserted-by":"crossref","first-page":"916472","DOI":"10.3389\/fphar.2022.916472","article-title":"Ruxolitinib as an effective and steroid-sparing first-line treatment in newly diagnosed BOS patients after hematopoietic stem cell transplantation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026061109155413000_63.3.2301727.53","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bbmt.2019.04.003","article-title":"Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation","volume":"25","author":"Abedin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.54","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2020.07.033","article-title":"Effect of ruxolitinib on lung function after allogeneic stem cell transplantation","volume":"26","author":"Bondeelle","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.55","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.12998\/wjcc.v8.i6.1065","article-title":"Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: results from a retrospective study on 38 Chinese patients","volume":"8","author":"Dang","year":"2020","journal-title":"World J Clin Cases"},{"key":"2026061109155413000_63.3.2301727.56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41409-019-0731-x","article-title":"Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study","volume":"55","author":"Escamilla G\u00f3mez","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.57","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41409-017-0068-2","article-title":"Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center","volume":"53","author":"Ferreira","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jtct.2021.06.002","article-title":"Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease","volume":"27","author":"Ferreira","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.59","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/bjd.15593","article-title":"Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease","volume":"177","author":"Hurabielle","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026061109155413000_63.3.2301727.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0081-5"},{"key":"2026061109155413000_63.3.2301727.61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","article-title":"Ruxolitinib as salvage therapy for chronic graft-versus-host disease","volume":"25","author":"Modi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.62","doi-asserted-by":"crossref","first-page":"8163780","DOI":"10.1155\/2019\/8163780","article-title":"Ruxolitinib for therapy of graft-versus-host disease","volume":"2019","author":"Neumann","year":"2019","journal-title":"Biomed Res Int"},{"key":"2026061109155413000_63.3.2301727.63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jtct.2021.10.015","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory\/dependent chronic graft-versus-host disease: real-world data and challenges","volume":"28","author":"Redondo","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.64","doi-asserted-by":"crossref","first-page":"673636","DOI":"10.3389\/fimmu.2021.673636","article-title":"Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2026061109155413000_63.3.2301727.65","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.2147\/DDDT.S338752","article-title":"Ruxolitinib for treatment of steroid-refractory graft-versus-host disease: real-world data from Chinese patients","volume":"15","author":"Wei","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2026061109155413000_63.3.2301727.66","doi-asserted-by":"crossref","first-page":"e2034750","DOI":"10.1001\/jamanetworkopen.2020.34750","article-title":"Evaluation of ruxolitinib for steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation","volume":"4","author":"Wu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026061109155413000_63.3.2301727.67","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.leukres.2021.106642","article-title":"Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience","volume":"109","author":"Xue","year":"2021","journal-title":"Leuk Res"},{"key":"2026061109155413000_63.3.2301727.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033122"},{"key":"2026061109155413000_63.3.2301727.69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00277-020-04273-2","article-title":"Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide","volume":"100","author":"Zhao","year":"2021","journal-title":"Ann Hematol"},{"key":"2026061109155413000_63.3.2301727.70","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac042"},{"key":"2026061109155413000_63.3.2301727.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012021"},{"key":"2026061109155413000_63.3.2301727.72","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026061109155413000_63.3.2301727.73","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"key":"2026061109155413000_63.3.2301727.74","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/bmt.2015.324","article-title":"Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation","volume":"51","author":"Del Fante","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2010.152","article-title":"Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT","volume":"46","author":"Lucid","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.21404","article-title":"Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation","volume":"31","author":"Brownback","year":"2016","journal-title":"J Clin Apher"},{"key":"2026061109155413000_63.3.2301727.77","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.bbmt.2018.04.012","article-title":"Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions","volume":"24","author":"Hefazi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-141481"},{"key":"2026061109155413000_63.3.2301727.79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12185-018-2483-6","article-title":"Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease","volume":"108","author":"Okamoto","year":"2018","journal-title":"Int J Hematol"},{"key":"2026061109155413000_63.3.2301727.80","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jca.21660","article-title":"Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: prospective single-center study","volume":"33","author":"Sakellari","year":"2018","journal-title":"J Clin Apher"},{"key":"2026061109155413000_63.3.2301727.81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704984"},{"key":"2026061109155413000_63.3.2301727.82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/ceji.2018.75831","article-title":"Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis","volume":"44","author":"Afram","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"2026061109155413000_63.3.2301727.83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jca.20084","article-title":"Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy","volume":"21","author":"Bisaccia","year":"2006","journal-title":"J Clin Apher"},{"key":"2026061109155413000_63.3.2301727.84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3907"},{"key":"2026061109155413000_63.3.2301727.85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbmt.2005.11.009","article-title":"Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?","volume":"12","author":"Couriel","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.86","first-page":"1096","article-title":"Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses","volume":"90","author":"Garban","year":"2005","journal-title":"Haematologica"},{"key":"2026061109155413000_63.3.2301727.87","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.transci.2021.103243","article-title":"Extracorporeal photopheresis in steroid-refractory chronic graft-versus-host disease: a retrospective multicenter study","volume":"60","author":"Dal","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"2026061109155413000_63.3.2301727.88","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/bmt.2012.156","article-title":"Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System","volume":"48","author":"Hautmann","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05586.x"},{"key":"2026061109155413000_63.3.2301727.90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.transci.2011.09.001","article-title":"Extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. The Hellenic experience: a study by the Hellenic Association of Hematology","volume":"46","author":"Tsirigotis","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"2026061109155413000_63.3.2301727.91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.transci.2004.02.003","article-title":"Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease","volume":"30","author":"Ilhan","year":"2004","journal-title":"Transfus Apher Sci"},{"key":"2026061109155413000_63.3.2301727.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.007"},{"key":"2026061109155413000_63.3.2301727.93","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2019.12.769","article-title":"Retrospective multicenter study of extracorporeal photopheresis in steroid-refractory acute and chronic graft-versus-host disease","volume":"26","author":"Oarbeascoa","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.94","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/16078454.2022.2095884","article-title":"Extracorporeal photopheresis for the treatment of chronic graft versus host disease","volume":"27","author":"Kansu","year":"2022","journal-title":"Hematology"},{"key":"2026061109155413000_63.3.2301727.95","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivw231"},{"key":"2026061109155413000_63.3.2301727.96","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1097\/TP.0000000000002693","article-title":"Favorable outcome of lung transplantation for severe pulmonary graft versus host disease: an Australian multicenter case series","volume":"103","author":"Kliman","year":"2019","journal-title":"Transplantation"},{"key":"2026061109155413000_63.3.2301727.97","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.197"},{"key":"2026061109155413000_63.3.2301727.98","doi-asserted-by":"crossref","first-page":"659","DOI":"10.21037\/atm-22-2517","article-title":"Lung transplantation for bronchiolitis obliterans after hematopoietic stem cell transplantation: a retrospective single-center study","volume":"10","author":"Liang","year":"2022","journal-title":"Ann Transl Med"},{"key":"2026061109155413000_63.3.2301727.99","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03187.x"},{"key":"2026061109155413000_63.3.2301727.100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11684-017-0538-3","article-title":"Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation","volume":"12","author":"Gao","year":"2018","journal-title":"Front Med"},{"key":"2026061109155413000_63.3.2301727.101","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318277e29e"},{"key":"2026061109155413000_63.3.2301727.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.07.086"},{"key":"2026061109155413000_63.3.2301727.103","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12378"},{"key":"2026061109155413000_63.3.2301727.104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2009.01155.x"},{"key":"2026061109155413000_63.3.2301727.105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03591.x"},{"key":"2026061109155413000_63.3.2301727.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.008"},{"key":"2026061109155413000_63.3.2301727.107","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01330-2017"},{"key":"2026061109155413000_63.3.2301727.108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12931-021-01699-8","article-title":"Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant","volume":"22","author":"Riddell","year":"2021","journal-title":"Respir Res"},{"key":"2026061109155413000_63.3.2301727.109","first-page":"5447","article-title":"Physical function after lung transplantation for late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Hamada","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026061109155413000_63.3.2301727.110","first-page":"1831","article-title":"Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation","volume":"30","author":"Hamada","year":"2022","journal-title":"Support Care Cancer"},{"key":"2026061109155413000_63.3.2301727.111","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318190b0be"},{"key":"2026061109155413000_63.3.2301727.112","first-page":"227","article-title":"Lung transplantation for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a single-center experience","volume":"25","author":"Shitenberg","year":"2023","journal-title":"Isr Med Assoc J"},{"key":"2026061109155413000_63.3.2301727.113","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1513\/AnnalsATS.201604-262OC","article-title":"Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant","volume":"13","author":"Cheng","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026061109155413000_63.3.2301727.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"2026061109155413000_63.3.2301727.115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/resp.13472","article-title":"Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome","volume":"24","author":"Kwok","year":"2019","journal-title":"Respirology"},{"key":"2026061109155413000_63.3.2301727.116","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7165"},{"key":"2026061109155413000_63.3.2301727.117","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.bbmt.2018.06.024","article-title":"Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning","volume":"24","author":"Duque-Afonso","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.118","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bbmt.2014.02.011","article-title":"Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation","volume":"20","author":"Thompson","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.119","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ppul.24801","article-title":"Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"55","author":"Walther","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026061109155413000_63.3.2301727.120","doi-asserted-by":"publisher","DOI":"10.1097\/00005382-200304000-00003"},{"key":"2026061109155413000_63.3.2301727.121","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2312030563"},{"key":"2026061109155413000_63.3.2301727.122","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jtct.2021.03.024","article-title":"Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease","volume":"27","author":"Turner","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026061109155413000_63.3.2301727.123","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"2026061109155413000_63.3.2301727.124","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30600-5"},{"key":"2026061109155413000_63.3.2301727.125","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"2026061109155413000_63.3.2301727.126","unstructured":"Anthony Nolan . COVID-19 Vaccines for Stem Cell Transplant Patients. Summary of Advice From the JCVI: Protecting Stem Cell Transplant Patients From COVID-19 with a Primary Course and Booster Vaccine Doses. https:\/\/www.anthonynolan.org\/sites\/default\/files\/2022-05\/Summary_of_JCVI_advice_on_Covid_vaccine_third_doses_for_SCT_patients_Apr22.pdf?page=125. Date last updated: April 2022."},{"key":"2026061109155413000_63.3.2301727.127","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.5"},{"key":"2026061109155413000_63.3.2301727.128","first-page":"101161","article-title":"Comprehensive pulmonary rehabilitation in patients with bronchiolitis obliterans syndrome: a case series","volume":"31","author":"Choi","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"2026061109155413000_63.3.2301727.129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2012.01.017","article-title":"Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"18","author":"Tran","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026061109155413000_63.3.2301727.130","unstructured":"World Health Organization (WHO) . WHO Framework Convention on Tobacco Control (WHO FCTC). Geneva, WHO, 2005."},{"key":"2026061109155413000_63.3.2301727.131","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.060"},{"key":"2026061109155413000_63.3.2301727.132","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060806"},{"key":"2026061109155413000_63.3.2301727.133","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-206865"},{"key":"2026061109155413000_63.3.2301727.134","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3608ST"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01727-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:16:12Z","timestamp":1781194572000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01727-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":134,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,28]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1183\/13993003.01727-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01727-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}